-

01:48:08 AM

SNOA Stock News

SNOA - Sonoma Pharmaceuticals Inc.

01/31/23 7:30 AM

Nasdaq : SNOA

partnershiplow float

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal

RHEA-AI

very positive

01/25/23 7:30 AM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal

RHEA-AI

very positive

01/04/23 7:30 AM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal

RHEA-AI

positive

11/14/22 4:15 PM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results

International sales increased by 18% in the six months ended September 30, 2022 compared to the same period prior year Gross profit percentage continues to trend upwards with the quarter ended September 30, 2022, coming in at 40% compared to 33% same period prior year Operating loss for the quarter

RHEA-AI

neutral

10/27/22 4:01 PM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care

RHEA-AI

neutral

10/06/22 4:15 PM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions,

RHEA-AI

neutral

08/11/22 4:30 PM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

Sonoma Pharmaceuticals, Inc.

RHEA-AI

neutral

08/02/22 4:30 PM

Nasdaq : SNOA

partnershiplow float

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,

RHEA-AI

very positive

07/13/22 4:45 PM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and

RHEA-AI

neutral

06/01/22 6:00 AM

Nasdaq : SNOA

covid-19low float

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that...

RHEA-AI

positive

SNOA Data

IndustryMedicinal and Botanical Manufacturing
Websitewww.sonomapharma.com
CeoAmy Trombly
Security nameSonoma Pharmaceuticals Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees20
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Medicinal and Botanical Manufacturing
Address645 Molly Lane, Suite 150
StateGeorgia
CityWoodstock
Zip30189
CountryUS
Phone18007599305

About Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company'sproducts are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.